☆ 4.2 Review

Emerging drugs for the treatment of alopecia areata

EXPERT OPINION ON EMERGING DRUGS (2022)

Related references

Note: Only part of the references are listed.

Article Dermatology

A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata

Daniela Mikhaylov et al.

Summary: This study evaluated the efficacy and safety of topical delgocitinib in moderate-to-severe alopecia areata through a double-blind, randomized, vehicle-controlled clinical trial. The results showed that this topical medication was not effective in treating moderate-to-severe alopecia areata, possibly due to its inability to penetrate deeply into the scalp dermis.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2023)

Add to Collection

Letter Dermatology

Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report

Mariateresa Cantelli et al.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

Oral tofacitinib for the treatment of alopecia areata in pediatric patients

Jon Kibbie et al.

Summary: Oral tofacitinib was clinically effective in the majority of patients and well tolerated in the treatment of pediatric patients with AA at the University of Colorado Hospital Dermatology Clinic. 72.7% of patients experienced hair regrowth with oral tofacitinib, while 27.3% experienced minimal to no hair regrowth. No serious adverse events were recorded during the observed treatment period.

PEDIATRIC DERMATOLOGY (2022)

Add to Collection

Review Chemistry, Medicinal

Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata

Hassiel Aurelio Ramirez-Marin et al.

Summary: Alopecia areata (AA) is a common autoimmune condition causing patchy hair loss, and there is currently no FDA-approved treatment specifically for AA. Ritlecitinib, a selective JAK3/TEC kinase inhibitor, has shown promising results in promoting hair regrowth and is being investigated for the treatment of other conditions. It offers advantages over other JAK inhibitors, with fewer side effects. Further research is needed to explore its long-term effects.

DRUG DESIGN DEVELOPMENT AND THERAPY (2022)

Add to Collection

Review Dermatology

TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors

Christine E. Jo et al.

Summary: This review discusses the role of cytokines in immune-mediated diseases and the potential application of JAK inhibitors and TYK2 inhibitors in the treatment of autoimmune diseases, focusing on three TYK2 inhibitors in clinical trials for dermatologic conditions.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Successful treatment of chronic severe alopecia areata with abrocitinib

Michaela Bennett et al.

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

Brett King et al.

Summary: This study assessed the safety and efficacy of CTP-543 in patients with chronic, moderate-to-severe AA. The results showed a significant reduction in the severity of AA in patients treated with CTP-543. However, further studies are needed to confirm its safety and efficacy due to the small sample size.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Editorial Material Dermatology

Assessing the efficacy of selective JAK inhibitors for alopecia areata with a patient-centered approach

H. A. Ramirez-Marin et al.

Summary: This article is about a study in dermatology and venereology, authored by R. Winnette et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Baricitinib in Alopecia Areata

Andrew Messenger et al.

Summary: For many individuals, alopecia areata is a temporary issue with hair loss patches recovering spontaneously within a few months. However, for a significant portion of patients, this condition can persist long-term and progress to complete baldness, with limited chances of recovery. Severe cases of alopecia often do not respond to medical treatments, leaving patients to struggle with the challenges it presents.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Dermatology

Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

Brett King et al.

Summary: The study aimed to evaluate the safety and efficacy of CTP-543 in patients with AA. The results showed a significant reduction in the severity of AA in patients receiving 8mg and 12mg of CTP-543, demonstrating promising treatment effects.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Review Dermatology

A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata

Kerry-Ann L. Dillon

Summary: Alopecia areata is a chronic and complex immune-mediated form of nonscarring alopecia with no specific approved treatment. However, the emerging use of janus kinase (JAK) inhibitors as targeted therapy in the management of Alopecia areata has shown promising results.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study

Rebekka Jerjen et al.

Summary: Oral tofacitinib shows promise as a systemic therapy for pediatric patients with alopecia areata, leading to significant improvement in Severity of Alopecia Tool (SALT) scores. The average improvement in SALT score after treatment was 67.7%, with mild adverse events reported.

PEDIATRIC DERMATOLOGY (2021)

Add to Collection

Review Medicine, Research & Experimental

Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options

A. Sterkens et al.

Summary: Patients with alopecia areata may experience hair loss in various regions of the body, and the exact pathology is still unknown. Available treatment options have limited effectiveness and potential side effects, with high relapse rates. Prognosis is uncertain and influenced by subtype and associated characteristics.

CLINICAL AND EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata

Samantha Eisman et al.

Summary: Alopecia areata is an inflammatory and autoimmune form of hair loss with limited therapeutic options. The novel oral JAK3-selective inhibitor Ritlecitinib shows promise as a potential therapy, with a unique mode of action and potentially superior safety profile over other JAK inhibitors. If approved, Ritlecitinib may become widely prescribed for severe AA patients in the future, and may also have potential applications in other hair loss disorders.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

Add to Collection

Article Dermatology

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

Brett King et al.

Summary: The study evaluated the efficacy and safety of baricitinib in patients with alopecia areata. The results showed that baricitinib was effective in patients with >= 50% scalp hair loss and well tolerated, supporting its use in this patient population.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis

Tamara Perez-Jeldres et al.

Summary: Sphingosine-1-phosphate (S1P) acts through 5 G-protein-coupled receptors to regulate lymphocyte trafficking and is involved in the pathogenesis of immune-mediated diseases. Modulators of S1P receptors have shown promise in treating diseases like multiple sclerosis and are being evaluated for other immune-related conditions.

DRUGS (2021)

Add to Collection

Article Dermatology

Gut microbiota characterization in Chinese patients with alopecia areata

Jinghao Lu et al.

Summary: The study found that the gut microbial composition of patients with alopecia areata was distinct from that of healthy controls, despite no significant differences in alpha-diversity. Three AA-associated microbial markers were identified using a random forest model, which may potentially be used for earlier diagnosis and as therapeutic targets.

JOURNAL OF DERMATOLOGICAL SCIENCE (2021)

Add to Collection

Article Dermatology

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

Brett King et al.

Summary: The study evaluated the efficacy and safety of two Janus kinase inhibitors, Ritlecitinib and Brepocitinib, in patients with alopecia areata, showing promising results in improving hair loss. However, two patients in the Brepocitinib group experienced serious adverse events.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Review Immunology

Resident Memory T Cells in Autoimmune Skin Diseases

Grace E. Ryan et al.

Summary: Tissue resident memory T cells (TRM) play a crucial role in the immune system by providing immediate and specific responses against pathogens re-infecting peripheral tissues. However, they have also been found to contribute to autoimmune diseases, where self-antigens continuously activate self-reactive TRM T cells, leading to destructive outcomes. This article focuses on how TRMs mediate disease in autoimmune skin conditions, such as vitiligo, psoriasis, cutaneous lupus erythematosus, alopecia areata, and frontal fibrosing alopecia.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims

Maryanne Senna et al.

Summary: This study found that patients with AA have a high burden of comorbidities and lack of treatment. Topical steroids and oral steroids are the most commonly used treatment methods. Healthcare costs incurred by patients with AA were mainly driven by outpatient and prescription costs.

ADVANCES IN THERAPY (2021)

Add to Collection

Letter Dermatology

Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata

Alessio Gambardella et al.

DERMATITIS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Results From a First-in-Human Study of BNZ-1, a Selective Multicytokine Inhibitor Targeting Members of the Common Gamma (γc) Family of Cytokines

Paul A. Frohna et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Add to Collection

Review Dermatology

Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis

L. Guo et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Add to Collection

Article Dermatology

Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study

Elise A. Olsen et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Review Dermatology

A hair-raising history of alopecia areata

David Broadley et al.

EXPERIMENTAL DERMATOLOGY (2020)

Add to Collection

Review Pharmacology & Pharmacy

JAK inhibition in the treatment of alopecia areata - a promising new dawn?

Fathima Ferial Ismail et al.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)

Add to Collection

Article Dermatology

The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata

Nekma Meah et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Article Rheumatology

Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Michael F. Robinson et al.

ARTHRITIS & RHEUMATOLOGY (2020)

Add to Collection

Review Multidisciplinary Sciences

Revisiting the PD-1 pathway

Nikolaos Patsoukis et al.

SCIENCE ADVANCES (2020)

Add to Collection

Article Pharmacology & Pharmacy

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers

Jingrui Liu et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection

Letter Dermatology

Ruxolitinib for the treatment of severe alopecia areata

Lucy Y. Liu et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Emerging drugs for alopecia areata: JAK inhibitors

Matilde Iorizzo et al.

EXPERT OPINION ON EMERGING DRUGS (2018)

Add to Collection

Article Dermatology

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

A. Jabbari et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)

Add to Collection

Article Dermatology

An appraisal of new treatment approaches and overview of current therapies

Lauren C. Strazzulla et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

Add to Collection

Article Chemistry, Medicinal

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-(2s,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-y1)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans

Atli Thorarensen et al.

JOURNAL OF MEDICINAL CHEMISTRY (2017)

Add to Collection

Article Dermatology

Tofacitinib for the treatment of alopecia areata and variants in adolescents

Brittany G. Craiglow et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

Add to Collection

Article

Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents

Lucy Yichu Liu et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2017)

Add to Collection

Article Gastroenterology & Hepatology

Hair Growth in Two Alopecia Patients after Fecal Microbiota Transplant

Dionne Rebello et al.

ACG CASE REPORTS JOURNAL (2017)

Add to Collection

Review Immunology

The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases

Yang Mao-Draayer et al.

CLINICAL IMMUNOLOGY (2017)

Add to Collection

Review Immunology

Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies

Amos Gilhar et al.

AUTOIMMUNITY REVIEWS (2016)

Add to Collection

Article Medicine, Research & Experimental

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

Milene Kennedy Crispin et al.

JCI INSIGHT (2016)

Add to Collection

Article

Industry Perspective on Alopecia Areata

Amanda T. Wagner

JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2015)

Add to Collection

Article Multidisciplinary Sciences

Pharmacologic inhibition of JAK-STAT signaling promotes hair growth

Sivan Harel et al.

SCIENCE ADVANCES (2015)

Add to Collection

Letter Dermatology

Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

Brittany G. Craiglow et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)

Add to Collection

News Item Biochemistry & Molecular Biology

Inhibiting Janus kinases to treat alopecia areata

Sherrie J. Divito et al.

NATURE MEDICINE (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

Luzhou Xing et al.

NATURE MEDICINE (2014)

Add to Collection

Review Medicine, General & Internal

Interventions for alopecia areata

F. M. Delamere et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2008)

Add to Collection

Review Immunology

PD-1 and PD-1 ligands: from discovery to clinical application

Taku Okazaki et al.

INTERNATIONAL IMMUNOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.